Immunic’s (IMUX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $8.00 target price on the stock.

Several other research firms have also commented on IMUX. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Thursday, October 16th. Roth Capital began coverage on shares of Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Chardan Capital raised Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, HC Wainwright cut their target price on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immunic presently has an average rating of “Buy” and a consensus target price of $7.40.

Immunic Trading Up 0.3%

NASDAQ:IMUX opened at $0.66 on Wednesday. The stock has a 50 day moving average of $0.66 and a 200-day moving average of $0.79. The firm has a market capitalization of $79.98 million, a PE ratio of -0.80 and a beta of 1.54. Immunic has a 52 week low of $0.51 and a 52 week high of $1.39.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. As a group, analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. Aberdeen Group plc raised its stake in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after buying an additional 7,184,457 shares in the last quarter. Millennium Management LLC grew its holdings in Immunic by 414.5% during the third quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after acquiring an additional 427,361 shares during the period. Focus Partners Wealth raised its position in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after acquiring an additional 415,104 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Immunic in the 3rd quarter valued at about $239,000. Finally, Vanguard Group Inc. boosted its position in shares of Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.